Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165048 | 0.84 | RARG (0.38) | DRD1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL10568486 | 0.81 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL10570522 | 0.81 | CYP3A4 (0.39) | CYP3A4 | |
| Hydrochloric Acid SCHEMBL6905279 | 0.81 | CYP1A2 (0.33) | DRD1CYP1A2CYP3A4CYP2C9TSHR | |
| Hydrochloric Acid SCHEMBL6905289 | 0.81 | CYP1A2 (0.33) | DRD1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6905286 | 0.80 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL31379754 | 0.77 | TNFRSF1A (0.37) | DRD1CYP3A4TSHR | |
| SCHEMBL7193235 | 0.75 | TSHR (0.49) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL3417517 | 0.72 | CYP2C19 (0.42) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL28318642 | 0.72 | TDP1 (0.38) | DRD1CYP1A2CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730626-B2 | TRANSITION METAL DERIVATIVE CAN REACT TO FORM AN IONIC COMPLEX WITH THE ALUMINOXANE | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| EP-1323723-A1 | TRANSITION METAL COMPOUNDS, POLYMERIZATION CATALYSTS FOR OLEFINS, OLEFIN POLYMERS AND PROCESS FOR THEIR PRODUCTION | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-20020193536-A1 | Transition metal compound, polymerization catalysts for olefins, olefin polymers and process for their production | IDEMITSU KOSAN CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193536-A1 | Transition metal compound, polymerization catalysts for olefins, olefin polymers and process for their production | CCNE2, PYM1, AP1M1 | DRD1 197/4885CYP1A2 1415/4885CYP3A4 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.